|
September 19, 2000
Loewen, Ondaatje, McCutcheon Ltd. initiates coverag of Neurochem Inc.
Neurochem Inc. (TSX : NRM) today announced that Loewen, Ondaatje, McCutcheon (LOM) has
initiated coverage of the Company. Copies of the report can be obtained by contacting
Neurochem.
" We are pleased that LOM has started its coverage just a few weeks after we started
trading on the TSX, " said Dr. Louis R. Lamontagne, President and CEO.
Secondary Amyloidosis is a systemic and fatal form of amyloidosis associated with chronic
diseases such as rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis,
Crohn's disease and Familial Mediterranean Fever. It is estimated that more than 500,000
patients in industrialized countries are presently suffering from Secondary Amyloidosis,
with no specific treatment available.
Neurochem is an industry leader in the development of a novel, proprietary series of
compounds that inhibit the formation, deposit and toxic effects of amyloid fibrils on
cells within the body. Neurochem's research team has been working with international
amyloid experts on the development of therapeutic cures to amyloid-related diseases,
including Alzheimer's disease, Secondary Amyloidosis , Diabetes Type II and Hemorrhagic
Stroke (due to Cerebral Amyloid Angiopathy). Neurochem has advanced three drug candidates to
clinical trials: Alzhemed™, for the treatment of Alzheimer's disease,
Fibrillex™, for Secondary Amyloidosis, and Cerebril™, for
Hemorrhagic Stroke. At present, the Company employs over 50 people and is located in
Saint-Laurent, Canada (www.neurochem.com).
For further Information, please contact:
Dr. Lise Hébert
Vice President, Corporate Communications
lhebert@neurochem.com
275 Armand-Frappier
Laval (Quebec)
H7V 4A7
Tel: (450) 680-4500
Fax: (450) 680-4501
|
